Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$32.11M$32.11Mderived−9.9% vs Q4 2012 Net Income-$3.67M-$3.67MderivedN/M vs Q4 2012 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$3,487,000−50.1% Operating Incomederived-$791,000N/M Operating Cash Flowderived-$3,749,000N/M Free Cash Flowderived-$3,919,000N/M Margins · derivedGross margin10.9%−8.7 pt vs Q4 2012
Operating margin-2.5%+64.7 pt vs Q4 2012
Net margin-11.4%+55.4 pt vs Q4 2012
ended Dec 31, 2013 · filed Mar 6, 2014 · 65 d after period end